First-line treatment for metastatic squamous cell lung cancer (mSCLC, age 60)First-line treatment for metastatic squamous cell lung cancer (mSCLC, age 60)
Editor's comments
For quite some time our survey and polling data showed that patients with mSCLC almost always received 1 of 2 regimens — carboplatin with either gemcitabine (Dr Wakelee’s current choice) or paclitaxel (Dr Ramalingam’s selection). However, following data presented by Dr Mark Socinski and others revealing a potential increase in response rate with nanoparticle albumin-bound (nab) paclitaxel in this patient subset, it appears that oncologists now turn to that drug in combination with a platinum almost as frequently as they do the others. survey data
 select references with links
Einhorn LH. First-line chemotherapy for non-small-cell lung cancer: Is there a superior regimen based on histology? J Clin Oncol 2008;26(21):3485-6. Abstract Scagliotti GV et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51. Abstract Socinski MA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol 2012;30(17):2055-62. Abstract |